The announcement disclosed on the evening of Andon Health Co.Ltd(002432) 14 that Liu Yi, the chairman and general manager of Andon Health Co.Ltd(002432) and Wu Tong, the Secretary of the board of directors, were supervised and talked because the information disclosed was incomplete.
The announcement said that the company recently received a copy of the decision on administrative supervision measures (hereinafter referred to as the “decision”) and the decision on taking regulatory conversation measures against Liu Yi and Wu Tong (Jin Jian Zheng measure [2022] No. 5) issued by Tianjin regulatory bureau of China Securities Regulatory Commission (hereinafter referred to as “Tianjin Securities Regulatory Bureau”).
According to the decision, on January 7, 2022, Andon Health Co.Ltd(002432) (hereinafter referred to as Andon Health Co.Ltd(002432) or the company) disclosed that on January 5, 2022 Beijing time, the company received the performance test report of the Radx project of the National Institutes of Health (NIH) on the household self-test OTC kit of ihealth covid-19 antigen against Omicron mutant virus arranged by the FDA, The report also said that “the ihealth-covid-19 antigen rapid test detected 100% of Omicron active virus samples with a maximum CT value of 21.59 (n = 5)”.
On January 15, 2022, when replying to the letter of concern from Shenzhen Stock Exchange, the company said that “100% of Omicron active virus samples with a maximum CT value of 21.59 (n = 5) were detected in the experiment”, in which “maximum” means that samples less than or equal to 21.59 can be detected 100%, and samples greater than 21.59 cannot be detected 100%, It also said that “the positive detection rate of all samples in the experimental group: when the CT value is ≤ 21.59, it can be detected completely, when the CT value is 22.86, it can be detected 60%, and when the CT value is ≥ 23.87, it can not be detected at all.”
Andon Health Co.Ltd(002432) only some successful test results were disclosed on January 7, 2022, but all the test results were not disclosed, and the disclosure information was incomplete.
Tianjin Securities Regulatory Bureau believes that Liu Yi, as the chairman and general manager of Andon Health Co.Ltd(002432) , and Wu Tong, as the Secretary of Andon Health Co.Ltd(002432) board of directors, bear the main responsibility for the integrity of information disclosure in the interim report of listed companies. During their term of office, they failed to faithfully and diligently perform their duties, violating the provisions of Article 4 of the measures for the administration of information disclosure of listed companies.
In accordance with the provisions of articles 51 and 52 of the measures for the administration of information disclosure of listed companies, Tianjin Securities Regulatory Bureau decided to take supervision and management measures for the two persons.
Andon Health Co.Ltd(002432) said that the company and relevant personnel attach great importance to the above administrative supervision measures, and will actively rectify in strict accordance with the supervision requirements, carefully summarize and draw lessons, strengthen the learning of relevant personnel on securities laws and regulations, and strengthen the awareness of standardized operation; At the same time, strengthen internal control and information disclosure management, effectively improve the standard operation level and information disclosure quality of the company, safeguard the interests of the company and all shareholders, and promote the healthy, stable and sustainable development of the company. The above administrative supervision measures have no significant impact on the operation of the company.
In the secondary market, as of the closing on the 14th, Andon Health Co.Ltd(002432) reported 55.15 yuan / share, down 6.64%, and the total market value of the company was 26.39 billion yuan.
